Contrasting of Flex Pharma Inc. (FLKS) and BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Flex Pharma Inc. (NASDAQ:FLKS) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Flex Pharma Inc. N/A 15.14 15.93M -1.22 0.00
BioSpecifics Technologies Corp. 34.00M 12.04 20.49M 2.73 24.24

In table 1 we can see Flex Pharma Inc. and BioSpecifics Technologies Corp.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Flex Pharma Inc. 0.00% -155.3% -128.1%
BioSpecifics Technologies Corp. 60.26% 0% 0%

Risk and Volatility

Flex Pharma Inc.’s 1.77 beta indicates that its volatility is 77.00% more volatile than that of S&P 500. BioSpecifics Technologies Corp.’s 24.00% more volatile than S&P 500 which is a result of the 1.24 beta.


Flex Pharma Inc.’s Current Ratio and Quick Ratio are 8.9 and 8.8 respectively. The Current Ratio and Quick Ratio of its competitor BioSpecifics Technologies Corp. are 27.1 and 27.1 respectively. BioSpecifics Technologies Corp. therefore has a better chance of paying off short and long-term obligations compared to Flex Pharma Inc.

Analyst Ratings

In next table is given Flex Pharma Inc. and BioSpecifics Technologies Corp.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Flex Pharma Inc. 0 0 0 0.00
BioSpecifics Technologies Corp. 0 0 1 3.00

Meanwhile, BioSpecifics Technologies Corp.’s average price target is $85, while its potential upside is 51.33%.

Insider and Institutional Ownership

Flex Pharma Inc. and BioSpecifics Technologies Corp. has shares held by institutional investors as follows: 13.7% and 63.5%. Flex Pharma Inc.’s share held by insiders are 16.9%. Competitively, insiders own roughly 0.1% of BioSpecifics Technologies Corp.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Flex Pharma Inc. -0.96% -35.72% 25.3% -22.03% -89.28% 21.58%
BioSpecifics Technologies Corp. -3.75% -1.43% -2.63% 14.13% 59.21% 9.16%

For the past year Flex Pharma Inc.’s stock price has bigger growth than BioSpecifics Technologies Corp.


BioSpecifics Technologies Corp. beats on 9 of the 11 factors Flex Pharma Inc.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.